PR Newswire
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
July 30, 2024
SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). The Phase 2, multi-center, randomized, double-blind, placebo-controlled study (NCT05483907) aims t